基于中性和耐药相关标记物基因分型对治疗失败的疗效试验中抗间日疟原虫药物的特征描述。
Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers.
机构信息
Vector Borne Diseases Unit, PNG Institute of Medical Research, Goroka, Papua New Guinea.
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4479-81. doi: 10.1128/AAC.01552-10. Epub 2011 Jun 27.
Abstract
Plasmodium vivax intervention trials customarily report uncorrected treatment failure rates. Application of recrudescence-reinfection genotyping and drug resistance single-nucleotide polymorphism typing to a 4-arm comparative efficacy trial illustrated that molecular approaches can assist in understanding the relative contributions of true drug resistance (recurrent with same genotype) and new infections to treatment failure. The PCR-corrected adequate clinical and parasitologic response may constitute an informative secondary endpoint in future P. vivax drug trials.
摘要
间日疟原虫干预试验通常报告未经校正的治疗失败率。应用复发再感染基因分型和药物耐药性单核苷酸多态性分型对四臂比较疗效试验的研究表明，分子方法有助于了解真正的药物耐药性（与相同基因型复发）和新感染对治疗失败的相对贡献。PCR 校正后的充分临床和寄生虫学反应可能成为未来间日疟原虫药物试验的一个有用的次要终点。
相似文献
1
Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers.基于中性和耐药相关标记物基因分型对治疗失败的疗效试验中抗间日疟原虫药物的特征描述。
Antimicrob Agents Chemother. 2011 Sep;55(9):4479-81. doi: 10.1128/AAC.01552-10. Epub 2011 Jun 27.
2
Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria.再燃、再感染还是复发？评估氯喹治疗间日疟原虫疟疾疗效的更严格框架。
J Infect Dis. 2019 Jan 7;219(2):315-322. doi: 10.1093/infdis/jiy484.
3
Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.耐药性间日疟原虫的表型和基因型特征。
Trends Parasitol. 2012 Nov;28(11):522-9. doi: 10.1016/j.pt.2012.08.005. Epub 2012 Oct 5.
4
Polymorphisms in genes associated with drug resistance of Plasmodium vivax in India.印度间日疟原虫耐药性相关基因的多态性
Parasitol Int. 2019 Jun;70:92-97. doi: 10.1016/j.parint.2019.03.001. Epub 2019 Mar 2.
5
Prevalence of drug resistance-associated gene mutations in Plasmodium vivax in Central China.中国中部地区间日疟原虫耐药相关基因突变的流行情况
Korean J Parasitol. 2012 Dec;50(4):379-84. doi: 10.3347/kjp.2012.50.4.379. Epub 2012 Nov 26.
6
Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal.尼泊尔两个地区间日疟原虫和恶性疟原虫抗疟药物耐药性的分子标志物流行情况。
Malar J. 2011 Apr 1;10:75. doi: 10.1186/1475-2875-10-75.
7
Island-wide diversity in single nucleotide polymorphisms of the Plasmodium vivax dihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka.斯里兰卡间日疟原虫二氢叶酸还原酶和二氢蝶酸合酶基因单核苷酸多态性的全岛多样性。
Malar J. 2007 Mar 9;6:28. doi: 10.1186/1475-2875-6-28.
8
Molecular monitoring of dihydrofolatereductase (dhfr) and dihydropteroatesynthetase (dhps) associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax isolates of Palawan, Philippines.菲律宾巴拉望间日疟原虫分离株中与磺胺多辛-乙胺嘧啶耐药性相关的二氢叶酸还原酶（dhfr）和二氢蝶酸合酶（dhps）的分子监测
Acta Trop. 2018 Apr;180:81-87. doi: 10.1016/j.actatropica.2018.01.006. Epub 2018 Jan 17.
9
Assessing the in vitro sensitivity with associated drug resistance polymorphisms in Plasmodium vivax clinical isolates from Delhi, India.评估来自印度德里的临床疟原虫 vivax 分离株的体外敏感性及其相关耐药突变。
Exp Parasitol. 2021 Jan;220:108047. doi: 10.1016/j.exppara.2020.108047. Epub 2020 Nov 20.
10
Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region.巴西亚马逊地区氯喹抗性间日疟原虫分离株crt-o和mdr1基因单核苷酸多态性分析
Antimicrob Agents Chemother. 2009 Aug;53(8):3561-4. doi: 10.1128/AAC.00004-09. Epub 2009 May 18.
引用本文的文献
1
Molecular detection of antimalarial drug resistance in from returned travellers to NSW, Australia during 2008-2018.2008年至2018年期间从澳大利亚新南威尔士州回国旅行者中抗疟药物耐药性的分子检测。
Pathogens. 2020 Feb 5;9(2):101. doi: 10.3390/pathogens9020101.
2
Malaria Epidemiology at the Clone Level.克隆水平的疟疾流行病学
Trends Parasitol. 2017 Dec;33(12):974-985. doi: 10.1016/j.pt.2017.08.013. Epub 2017 Sep 28.
3
Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.固定剂量青蒿琥酯-阿莫地喹组合与氯喹治疗巴西亚马逊地区单纯性间日疟原虫血液期感染的疗效比较：一项开放标签随机对照试验
Clin Infect Dis. 2017 Jan 15;64(2):166-174. doi: 10.1093/cid/ciw706. Epub 2016 Oct 20.
4
Diagnosis and Treatment of Plasmodium vivax Malaria.间日疟的诊断与治疗
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):35-51. doi: 10.4269/ajtmh.16-0171. Epub 2016 Oct 5.
5
Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea.巴布亚新几内亚两个地区与恶性疟原虫和间日疟原虫耐药性相关的突变流行率存在显著地理差异。
Malar J. 2015 Oct 9;14:399. doi: 10.1186/s12936-015-0879-9.
6
Plasmodium vivax Diversity and Population Structure across Four Continents.四大洲间间日疟原虫的多样性与种群结构
PLoS Negl Trop Dis. 2015 Jun 30;9(6):e0003872. doi: 10.1371/journal.pntd.0003872. eCollection 2015.
7
Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study.蒿甲醚-本芴醇与青蒿素-萘喹在巴布亚新几内亚患单纯性疟疾儿童中的疗效比较：治疗后六个月随访研究
Malar J. 2015 Mar 21;14:121. doi: 10.1186/s12936-015-0624-4.
8
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial.青蒿素萘酚喹与蒿甲醚-本芴醇治疗巴布亚新几内亚儿童单纯性疟疾的开放标签随机试验。
PLoS Med. 2014 Dec 30;11(12):e1001773. doi: 10.1371/journal.pmed.1001773. eCollection 2014 Dec.
9
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis.间日疟原虫氯喹耐药的全球范围：一项系统评价和荟萃分析
Lancet Infect Dis. 2014 Oct;14(10):982-91. doi: 10.1016/S1473-3099(14)70855-2. Epub 2014 Sep 8.
10
Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.单剂磷酸萘酚喹在巴布亚新几内亚儿童中的药代动力学特征：短程大剂量方案根治间日疟的可行性。
Antimicrob Agents Chemother. 2014;58(1):432-9. doi: 10.1128/AAC.01437-13. Epub 2013 Nov 4.
本文引用的文献
1
The international limits and population at risk of Plasmodium vivax transmission in 2009.2009 年按蚊传播间日疟原虫的国际界限和危险人群。
PLoS Negl Trop Dis. 2010 Aug 3;4(8):e774. doi: 10.1371/journal.pntd.0000774.
2
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.乌干达坎帕拉儿童中蒿甲醚-本芴醇和青蒿琥酯-阿莫地喹的药代动力学。
Antimicrob Agents Chemother. 2010 Jan;54(1):52-9. doi: 10.1128/AAC.00679-09. Epub 2009 Oct 19.
3
Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite.间日疟原虫，一种被忽视的人类疟原虫，在知识方面存在关键空白。
Lancet Infect Dis. 2009 Sep;9(9):555-66. doi: 10.1016/S1473-3099(09)70177-X.
4
5
Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials.间日疟原虫基因分型标记物在临床试验中用于分子监测的评估。
J Infect Dis. 2009 Apr 1;199(7):1074-80. doi: 10.1086/597303.
6
A trial of combination antimalarial therapies in children from Papua New Guinea.在巴布亚新几内亚儿童中进行的联合抗疟疗法试验。
N Engl J Med. 2008 Dec 11;359(24):2545-57. doi: 10.1056/NEJMoa0804915. Epub 2008 Dec 8.
7
Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes.马达加斯加间日疟原虫对氯喹的耐药性：pvmdr1和pvcrt - o基因的临床疗效及多态性
Antimicrob Agents Chemother. 2008 Dec;52(12):4233-40. doi: 10.1128/AAC.00578-08. Epub 2008 Sep 22.
8
Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1.间日疟原虫体内对阿莫地喹加磺胺多辛-乙胺嘧啶耐药性的分子标志物：pvdhfr和pvmdr1中的突变
J Infect Dis. 2008 Aug 1;198(3):409-17. doi: 10.1086/589882.
9
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia.与严重和致命疟疾相关的多重耐药间日疟原虫：印度尼西亚巴布亚的一项前瞻性研究。
PLoS Med. 2008 Jun 17;5(6):e128. doi: 10.1371/journal.pmed.0050128.
10
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea.间日疟原虫及混合感染与儿童重症疟疾相关：来自巴布亚新几内亚的一项前瞻性队列研究
PLoS Med. 2008 Jun 17;5(6):e127. doi: 10.1371/journal.pmed.0050127.
Zotero 插件